AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

AstraZeneca (AZN) announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a private clinical-stage biotech company developing novel treatments for rare endocrine diseases.The impending acquisition is set to strengthen AZN’s late-stage rare disease pipeline and expand its bone metabolism franchise by adding late-stage pipeline candidate, eneboparatide (AZP-3601).Eneboparatide, a PTH receptor 1 agonist with a novel mechanism of action, is Amolyt Pharma’s investigational candidate, ...